Tumor immune microenvironment and immunotherapy efficacy in braf mutation non-small-cell lung cancer

HIGHLIGHTS

• who: Hui Li from the (UNIVERSITY) have published the paper: Tumor immune microenvironment and immunotherapy efficacy in BRAF mutation non-small-cell lung cancer, in the Journal: (JOURNAL) of 19/09/2022
• what: This study was approved by the Institutional Review Board of Zhejiang Cancer Hospital and Hunan Cancer Hospitals (ID: IRB2020-240), and written informed consent was obtained from individual patients before enrollment. Given that combination of ICIs and chemotherapy resulted in an ORR of 63.3%, median PFS of 11.0 months, and median OS of 20.3 months in BRAF V600E mutated . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.